True North Labs

Category: Research

  • Tesamorelin: A Standout Example of an FDA-Approved Peptide Success Story

    Tesamorelin: A Standout Example of an FDA-Approved Peptide Success Story

    Tesamorelin holds a distinctive place in the world of peptide science: it is one of the relatively few peptides to have earned full FDA approval, giving it a level of regulatory validation that many other investigational peptides have yet to achieve. As a growth hormone-releasing hormone (GHRH) analog, tesamorelin works by stimulating the body’s own natural growth hormone production pathways rather than introducing synthetic growth hormone directly, an approach that reflects a broader shift toward more physiologically-guided peptide therapies.

    What makes tesamorelin particularly noteworthy for peptide researchers and clinicians is its documented path through clinical trials and regulatory review. Unlike many peptides that remain in early research or compounding-pharmacy gray areas, tesamorelin’s approval process means it has been subject to the rigorous safety and efficacy standards the FDA requires. This track record serves as a useful reference point for how peptide-based therapies can successfully navigate the regulatory system when supported by solid clinical evidence.

    Its unique mechanism, working upstream to encourage the body’s natural hormone signaling rather than overriding it, has also made tesamorelin a frequently cited example in discussions about the future direction of peptide therapeutics. Researchers studying growth hormone pathways often point to it as a model for how targeted, receptor-specific peptides can be designed with a clear physiological rationale.

    For the peptide research community, tesamorelin’s story is an encouraging signal. It demonstrates that with proper trial design and regulatory diligence, peptide-based approaches can move from promising laboratory concepts to approved clinical tools. As interest in GHRH analogs and related peptides continues to grow, tesamorelin stands as a benchmark for what a well-supported, thoroughly vetted peptide therapy can look like.

    This article is for informational purposes only and is not intended as medical advice. Anyone interested in learning more about tesamorelin or peptide therapies should consult a qualified healthcare provider.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Tesamorelin Explained: The FDA-Approved GHRH Analog That Sits in a Unique Position in Peptide Research – Haute Living

  • Understanding C-Peptide: A Key Biomarker Advancing Type 1 Diabetes Research

    Understanding C-Peptide: A Key Biomarker Advancing Type 1 Diabetes Research

    Researchers and clinicians studying type 1 diabetes (T1D) increasingly rely on a small but informative molecule called C-peptide to track how much insulin-producing capacity a person’s body still has. Because C-peptide is released in equal amounts alongside naturally produced insulin, measuring it gives scientists a reliable window into beta-cell activity—even in people who are taking insulin therapy themselves.

    This distinction matters because it allows researchers to separate a person’s own insulin production from injected or pump-delivered insulin. That clarity has become especially valuable in clinical trials aimed at preserving or restoring beta-cell function, since C-peptide levels can show whether a new treatment is helping the pancreas maintain its own insulin-making ability over time.

    Advocacy and research organizations focused on type 1 diabetes have highlighted C-peptide testing as a practical tool that is already being used in studies of immunotherapies, beta-cell replacement approaches, and other emerging treatments. By giving researchers a consistent, measurable marker, C-peptide helps make trial results more meaningful and comparable across different studies and patient groups.

    For people living with T1D, this kind of biomarker research is an encouraging sign of how the field is maturing. Better measurement tools mean that promising new therapies can be evaluated more precisely, potentially speeding up the path from early-stage research to real-world treatment options. It also reflects a broader trend in diabetes science: using biological signals the body already produces to guide the development of smarter, more targeted interventions.

    As research continues, C-peptide is likely to remain a valuable reference point for scientists working to understand—and eventually protect or restore—natural insulin production in people with type 1 diabetes. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: C-peptide: Everything You Need to Know – Breakthrough T1D

  • Report Projects Continued Growth for Global Peptide Therapeutics Market Through 2035

    Report Projects Continued Growth for Global Peptide Therapeutics Market Through 2035

    A recently published market analysis outlines projected growth for the global peptide therapeutics industry through 2035, adding to a growing body of industry reports tracking this segment of the pharmaceutical and biotechnology sectors. While specific figures vary across research firms, such reports generally point to steady expansion driven by increased research funding, a growing pipeline of peptide-based candidates, and wider interest from pharmaceutical companies in peptide chemistry as a drug development platform.

    Peptide therapeutics are short chains of amino acids designed to interact with specific biological targets, such as receptors or enzymes, in the body. Because they can offer a balance between the specificity of large biologic drugs and the manufacturability of small-molecule chemicals, peptides have attracted sustained interest for conditions ranging from metabolic disorders to oncology and rare diseases. Advances in synthesis techniques, delivery methods, and stability improvements have also made peptides more attractive to drug developers compared to earlier decades, when rapid breakdown in the body limited their practical use.

    Market research reports like this one typically compile data from public financial disclosures, clinical trial registries, patent filings, and industry surveys to estimate current market size and forecast future trends. These projections are commonly used by investors, pharmaceutical companies, and policymakers to gauge where research and manufacturing investment may be headed. However, such forecasts are inherently estimates and can be influenced by assumptions about regulatory approvals, manufacturing capacity, and broader economic conditions, meaning actual outcomes may differ from projected figures.

    Several factors are frequently cited across industry analyses as contributing to interest in the peptide therapeutics space. These include the continued expansion of peptide-based treatments for metabolic and weight-related conditions, ongoing research into peptide applications for autoimmune and inflammatory diseases, and improvements in manufacturing processes that have historically made peptide production more costly than small-molecule drugs. Growth in contract manufacturing and biotechnology infrastructure in various regions has also been noted as a supporting factor in some reports.

    For readers following the peptide space, market size reports offer a useful, if broad, snapshot of where commercial and research attention is concentrated, though they should be distinguished from clinical or regulatory developments regarding any individual peptide compound. As with any industry forecast, the numbers reflect modeled projections rather than guaranteed outcomes, and actual market developments will depend on future research results, regulatory decisions, and shifts in healthcare policy.

    This article is for informational purposes only and does not constitute medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only — not medical advice.

    Source: Peptide Therapeutics Market Size & Global Trends [2035] – Market Research Future

  • Peptide and Nanobody Drug Conjugates Gain Momentum as Targeted Therapy Platforms

    Drug conjugates—molecules that pair a targeting component with a therapeutic payload—have long been dominated by antibody-drug conjugates (ADCs), which use full-sized antibodies to guide cytotoxic agents to cancer cells. Recent industry coverage points to a rapid expansion of a related but distinct approach: conjugates built on peptides and nanobodies, smaller molecular scaffolds that can offer some advantages over conventional antibodies while introducing their own design considerations.

    Peptides are short chains of amino acids that can be engineered to bind selectively to receptors or proteins found on particular cell types. Nanobodies, derived from the single-domain antibody fragments found in camelid species such as llamas and alpacas, retain antigen-binding capability but are a fraction of the size of standard antibodies. Because both formats are smaller and structurally simpler than full antibodies, they can potentially penetrate tissues more readily, be manufactured through more straightforward chemical or biological processes, and be engineered with greater flexibility in how a payload is attached.

    These properties have made peptide and nanobody conjugates attractive across a range of applications, including oncology, imaging, and other disease areas where precise delivery of a drug or diagnostic agent to a specific tissue is important. Proponents of the approach suggest that smaller targeting molecules may reduce certain manufacturing complexities associated with large antibody proteins, while still allowing for conjugation to cytotoxic drugs, radioisotopes, or other therapeutic payloads. At the same time, smaller scaffolds can face their own hurdles, such as shorter circulation times in the body, which developers address through chemical modifications or formulation strategies.

    The reported growth in this space suggests increasing interest from biotechnology and pharmaceutical developers in diversifying the toolkit used for targeted therapies beyond traditional ADCs. As with any emerging drug class, peptide and nanobody conjugates must still progress through preclinical evaluation and clinical trials to establish safety and efficacy before they can be considered for broader use. Researchers continue to study how factors like binding affinity, linker chemistry, and payload selection influence performance, and regulatory pathways for these newer conjugate formats are still being clarified as more candidates advance through development.

    Overall, the expansion of peptide and nanobody drug conjugates illustrates a broader trend in pharmaceutical research: the search for targeting platforms that balance precision, manufacturability, and adaptability. Whether these approaches will match or complement the clinical track record established by antibody-drug conjugates remains an active area of investigation as more candidates move through trials. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only — not medical advice.

    Source: Rapid Expansion Of Peptide And Nanobody Drug Conjugates – Clinical Leader